Cas 866774-37-0,(R)-(-)-3-cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-propionic acid

866774-37-0

Post Buying Request

Basic information

Product Name: (R)-(-)-3-cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-propionic acid
Synonyms: (R)-(-)-3-cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-propionic acid
CAS NO:866774-37-0
Molecular Formula:
Molecular Weight: 380.508
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: (R)-(-)-3-cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-propionic acid(CAS DataBase Reference)
NIST Chemistry Reference: (R)-(-)-3-cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-propionic acid(866774-37-0)
EPA Substance Registry System: (R)-(-)-3-cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-propionic acid(866774-37-0)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 866774-37-0(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

866774-37-0 Suppliers

Recommended suppliers

866774-37-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 866774-37-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,6,7,7 and 4 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 866774-37:
(8*8)+(7*6)+(6*6)+(5*7)+(4*7)+(3*4)+(2*3)+(1*7)=230
230 % 10 = 0
So 866774-37-0 is a valid CAS Registry Number.

866774-37-0Upstream product

866774-36-9 3-cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)phenyl]propionic acid

866774-37-0Downstream Products

866774-37-0Relevant academic research and scientific papers

SULFONAMIDE-THIAZOLPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS USEFUL THE TREATMENT OF TYPE 2 DIABETES

-

Page/Page column 48-49, (2010/02/14)

The present invention provides compounds of the formula (I), which are activators of glucokinase activity and, thus, may be employed as therapeutic agents for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) may be employed for the prevention and the treatment of impaired glucose tolerance, Type 2 diabetes and obesity.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 866774-37-0